Intravenous immunoglobulin and Guillain-Barré syndrome

Clinical Reviews in Allergy and Immunology

Volumn 29, Issue 3, 2005, Pages 281-287

  Harel, Michal ^a   Shoenfeld, Yehuda ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Anti GM1; Axonal; Dosage; Efficacy; Guillain Barr syndrome; Intravenous immunoglobulin; Pediatric; Plasma exchange; Safety

Indexed keywords

IMMUNOGLOBULIN; METHYLPREDNISOLONE; STEROID;

ANAPHYLAXIS; ARTICLE; ASEPTIC MENINGITIS; ATELECTASIS; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEVER; GUILLAIN BARRE SYNDROME; HEART INFARCTION; HEMODYNAMICS; HUMAN; HYPOCALCEMIA; HYPOTENSION; IMMUNOMODULATION; INJECTION SITE REACTION; KIDNEY FAILURE; KIDNEY TUBULE NECROSIS; MALAISE; MENINGISM; NAUSEA; NONHUMAN; PATIENT; PLASMAPHERESIS; PNEUMONIA; SEPTICEMIA; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 29944438453     PISSN: 10800549     EISSN: None     Source Type: Journal    
DOI: 10.1385/CRIAI:29:3:281     Document Type: Article

References (21)

1. Kuwabara, S. (2004), Drugs 64, 597-610.
2. Dalakas, M. C. (2004), JAMA 291, 2367-2375.
3. Czaplinski, A. and Steck, A. J. (2004), J Neurol 251, 127-137.
4. Ibanez, C. and Montoro-Ronsano J. B. (2003), Curr Pharm Biotechnol 4, 239-247.
5. Zhang, G., Lopez, P. H. H., Li, C. I., et al. (2004), Brain 127, 1085-1100.
6. Stabgel, M., Toyka, K. V., and Gold, R. (1999), Arch Neurol 56, 661-663.
7. Nishimoto, Y., Koga, M., Kamijo, M., Hirata, K., and Yuki, N. (2004), Neurology 62, 1939-1944.
8. van der Meche, F. G. and Schmitz, P. I. (1992), N Engl J Med 326, 1123-1129.
9. Bril, V., Ilse, W. K., Pearce, R., Dhanani, A., Sutton, D., and Kong, K. (1996), Neurology 46, 100-103.
10. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. (1997), Lancet 349, 225-230.
11. van Koningsveld, R., Schmitz, P. I., Meche, F. G., Visser, L. H., Meulstee, J., van Doorn, P. A.; Dutch GBS Study Group (2004), Lancet 363, 192-196.
12. Jacobs, B. C., van Doorn, P. A., Schmitz, P. I., et al. (1996), Ann Neurol 40, 181-187.
13. Kuwabara, S., Mori, M., Ogawara, K., et al. (2001), Muscle Nerve 24, 54-58.
14. Dada, M. A. and Kaplan, A. A. (2004) Ther Apher Dial 8, 409-412.
15. Gurses, N., Uysal, S., Cetinkaya, F., Islek, I. and Kalayci, A.G. (1995), Scand J Infect Dis 27, 241-243.
16. Yata, J., Nihei, K., Ohya, T., et al.; Study Group for Pediatric Guillain-Barré Syndrome. (2003), Pediatr Int 45, 543-549.
17. Shahar, E. and Leiderman, M. (2003), Clin Neuropharmacol 26, 84-87.
18. Raphael, J. C., Chevret, S., Harboun, M., and Jars-Guincestre, M. C.; French Guillain-Barré Syndrome Cooperative Group. (2001), J Neurol Neurosurg Psychiatry 71, 235-238.
19. Katz, U. and Orbach, H. (2005), Clin Rev Allergy Immunol This issue.
20. Dalakas, M. C. (2004), Pharmacol Ther 102, 177-193.
21. Hughes, R. A., Wijdicks, E. F., Barohn, R., et al.; Quality Standards Subcommittee of the American Academy of Neurology. (2003), Neurology 61, 736-740.